在心力衰竭患者中,心脏再同步治疗和细胞因子之间的相互作用
Seyyed Shamsadin Athari1, Entezar Mehrabi Nasab2, Kai Jing3
1Department of Immunology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Cytokine
|January 10, 2024
概括
充血性心力衰竭涉及免疫系统的激活和细胞因子风暴. 心脏再同步疗法 (CRT) 提供了一种有前途的基于设备的方法来管理炎症并改善心力衰竭患者的结果.
科学领域:
- 免疫学 免疫学 免疫学
- 心脏病学 心脏病学
- 医疗器械 医疗器械
背景情况:
- 充血性心力衰竭 (CHF) 是一种复杂的疾病,具有重大的社会成本.
- 心肌损伤会触发免疫反应,包括白细胞增殖和细胞因子风暴,有助于CHF的发病和重塑.
- 目前治疗心力衰竭的药物治疗有局限性,持续的炎症起着关键作用.
研究的目的:
- 审查与心力衰竭的发展和进展有关的免疫过程.
- 调查心脏再同步疗法 (CRT) 在减轻与心力衰竭相关的细胞因子风暴中的有效性.
- 突出CRT作为心力衰竭管理的新,非药物治疗选择.
主要方法:
- 关于心力衰竭中的免疫机制的文献综述.
- 分析评估CRT对炎症标志物和细胞因子水平的影响的研究.
- 综合当前关于CRT在心力衰竭治疗中的作用的理解.
主要成果:
- 炎症过程,特别是细胞因子风暴,是心力衰竭病原和进展的组成部分.
- 心脏再同步疗法 (CRT) 在调节炎症反应和控制心力衰竭患者的细胞因子风暴方面表现出潜力.
- CRT是一种有效的基于设备的疗法,补充了传统治疗方法.
结论:
- 了解心力衰竭的免疫基础对于开发有效的治疗方法至关重要.
- 心脏再同步疗法 (CRT) 显示出作为心力衰竭的免疫调节疗法具有前景.
- 通过解决炎症途径,CRT提供了一种有价值的治疗策略,用于管理心力衰竭.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432
01:26Heart Failure Drugs: Inotropic Agents
591
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
591
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:22Heart Failure Drugs: β-Blockers
341
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
01:22Heart Failure Drugs: Diuretics
384
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
384